Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 1.00 |
| ▸ | P2RY4 | P51582 | 11/20 | 1.00 |
| ▸ | POLA1 | P09884 | 1/20 | 0.75 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.62 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21006621 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL18574166 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL14853738 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL16368333 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL19558286 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL14946253 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL14853792 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL17972338 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL38662433 | 0.98 | P2RY2 (0.96) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL790121 | 0.92 | P2RY2 (0.84) | P2RY2P2RY4POLA1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20190175759-A1 | METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175758-A1 | METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175757-A1 | METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXIN | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175756-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175760-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190167809-A1 | METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20190167808-A1 | METHODS OF TREATING PHENYLKETONURIA WITH MRNA ENCODING PHENYLALANINE HYDROXYLASE (PAH) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20180311379-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-11-01 | — | — | US | claimed |
| US-20180161454-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-14 | — | — | US | claimed |
| US-20180161452-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-14 | — | — | US | claimed |
| US-20180161453-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-14 | — | — | US | claimed |
| US-20180126005-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-05-10 | — | — | US | claimed |
| US-20180117179-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-05-03 | — | — | US | claimed |
| US-20170128549-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-05-11 | — | — | US | claimed |
| US-20170065727-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-03-09 | — | — | US | claimed |
| US-20170000858-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-01-05 | — | — | US | claimed |
| US-20160367704-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-12-22 | — | — | US | claimed |
| US-20160184406-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-06-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885POLA1 664/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885POLA1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.